

CURRENT REPORT 13/2022

July 26, 2022

Changes in Ryvu's Management Board

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow ("Company", "Ryvu") hereby informs that Company's Supervisory Board, acting pursuant to art. 368 § 4 of the Polish Commercial Companies Code, appointed on July 25th, 2022 Mr. Vatnak Vat-Ho and Mr. Hendrik Nogai, M.D. to the Management Board of the Company, effective August 1st, 2022.

Mr. Vatnak Vat-Ho has been Ryvu's Chief Business Officer since April, 2021. Mr. Vat-Ho has been responsible for a wide scope of corporate and business development activities at Ryvu including strategic positioning, partnering discussions, alliance management as well as investor interactions.

Dr. Nogai has been appointed Ryvu's Chief Medical Officer in January, 2022. Dr. Nogai has been leading medical, clinical, and regulatory functions to support and guide the development of the company's clinical pipeline.

Information regarding the education, qualifications and positions previously held by Mr. Vat-Ho and Dr. Nogai, along with their past job experience, is attached to this report.

Mr. Vat-Ho and Dr. Nogai are not listed in the Registry of Insolvent Debtors maintained on the basis of the National Court Registry act, do not engage in competition with Ryvu Therapeutics S.A, are not partners in civil law partnerships or limited companies which engage in such competition and are not members of any official bodies of other legal entities which engage in such competition.

Legal basis: Art. 56 section 1 item 2 of the Act on Public Offering - current and periodic information in connection with par. 5 points 4 and 5 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required by the laws of a non-member state (Journal of Laws of 2018, item 757)

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board

[ENGLISH VERSION BELOW]

Hendrik Nogai, M.D.

Dr Nogai od lutego 2022 r. pełni rolę Dyrektora ds. Medycznych w Ryvu. Hendrik Nogai jest dyplomowanym lekarzem medycyny w dziedzinie hematologii/onkologii i chorób wewnętrznych. Hendrik Nogai posiada niemal 10-letnie doświadczenie w opiece nad pacjentami i prowadzeniu badań podstawowych w różnych środowiskach akademickich. Dr Nogai posiada 17-letnie doświadczenie branżowe, w tym w zakresie doradztwa biznesowego w Mercer Management Consulting/Oliver Wyman, doradztwa medycznego dla Nordic Biotech Capital ApS, a także poprzez zajmowane stanowiska kierownicze w firmie Bayer AG, gdzie ostatnio pełnił funkcję wiceprezesa programu Global Development Leader NTRK.

Dr Nogai ukończył studia medyczne na Charité - Uniwersytecie Medycznym w Berlinie, Uniwersytecie Ludwika i Maksymiliana w Monachium oraz na Harvard Medical School w Bostonie. Ponadto uzyskał stopień doktora na Uniwersytecie Humboldtów w Berlinie za badania w obszarze biologii komórki, które prowadził w Niemieckim Centrum Badań nad Reumatyzmem w Berlinie.

Pan Vatnak Vat-Ho, MBA

Pan Vat-Ho objął funkcję Chief Business Officer w Ryvu w kwietniu 2021 roku, wnosząc do Spółki 20-letnie doświadczenie zawodowe w obszarze farmacji, biotechnologii oraz rynków kapitałowych. Vatnak Vat-Ho przez pierwsze 10 lat swojej kariery zawodowej pracował w różnych bankach inwestycyjnych i globalnych funduszach kapitałowych, a następnie przez 8 lat pracował w firmie Pfizer, gdzie pełnił kilka funkcji, w tym Starszego Dyrektora/Kierownika Zespołu ds. Strategii, Rozwoju Biznesu i Współpracy. Przed dołączeniem do Ryvu, Vat-Ho zajmował stanowisko Wiceprezesa ds. Rozwoju Biznesu w Affimed Inc., gdzie był odpowiedzialny za prowadzenie działań partneringowych zarówno dla projektów w fazie przedklinicznej, jak i klinicznej, w spółce pełnił również funkcję Kierownika ds. Współpracy.

Pan Vat-Ho uzyskał tytuł licencjata z biologii na Uniwersytecie Harvarda oraz tytuł MBA w Leonard N. Stern School of Business na Uniwersytecie Nowojorskim.

Hendrik Nogai, M.D.

Dr. Nogai has served as Chief Medical Officer at Ryvu since February 2022. He is a board-certified medical doctor in Hematology/Oncology as well as in Internal Medicine, with almost 10 years of experience in patient care and basic research in various academic settings. Besides his clinical expertise, Dr. Nogai has 17 years of industry experience including business consulting at Mercer Management Consulting/ Oliver Wyman, a Medical Advisor role at Nordic Biotech Capital ApS, and positions of increasing responsibility at Bayer AG, with his most recent role of Vice President, Global Development Leader NTRK program.

Dr. Nogai completed his Medical Studies at Charité – University Medicine Berlin (Germany), Ludwig-Maximilians University in Munich (Germany), and Harvard Medical School in Boston (USA). He holds a doctoral degree awarded by the Humboldt University of Berlin (Germany) for his research on cell biology conducted at the DRFZ in Berlin.

Mr. Vatnak Vat-Ho, MBA

Mr. Vat-Ho has been Ryvu's Chief Business Officer since April 2021 and has 20 years of experience in pharma, biotech, as well as capital markets expertise. Vatnak Vat-Ho spent the first 10 years of his professional career in a variety of investment banks and global equity healthcare funds followed by 8 years at Pfizer where he held several roles, concluding in the position of Senior Director/Team Lead, Strategy, Business Development & Alliances in the commercial development organization. Most recently Mr. Vat-Ho served as Vice President, Business Development at Affimed Inc. where he was responsible for leading partnering activities for both the preclinical and clinical pipeline, as well as serving as alliance manager for the company's collaborations.

Mr. Vat-Ho received his AB degree in Biology from Harvard University, and MBA from New York University's Leonard N. Stern School of Business.